FDA "consent agreement" with THA investigator
Executive Summary
Confirmed in May 4 letter from FDA Scientific Investigations Division Director Frances Kelsey, PhD, MD, to William Summers, MD. After receiving from Summers a "plan of continued compliance of clinical investigation" on April 10, Kelsey stated: "We consider your plan to represent a consent agreement with the agency, and to indicate our concurrence have signed it." Summers submitted the plan, outlining his intention to conduct investigations in accordance with FDA regs, to avoid being disqualified by the agency as an acceptable clinical investigator. The agency informed Summers of problems in the conduct and reporting of his study in early 1988. Published in the Nov. 13, 1986 New England Journal of Medicine, the study suggested dramatic improvement in patients taking tetrahydroaminoacridine (THA). . . .
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.